Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $19.00 at Guggenheim

Sarepta Therapeutics (NASDAQ:SRPT) had its target price trimmed by Guggenheim from $22.00 to $19.00 in a research report released on Wednesday,Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on SRPT. Leerink Partners increased their price objective on Sarepta Therapeutics from $12.00 to $15.00 and gave the stock a “market perform” rating in a report on Tuesday, September 9th. Needham & Company LLC restated an “underperform” rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. Jefferies Financial Group cut their price objective on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating on the stock in a research note on Thursday, July 24th. JPMorgan Chase & Co. upgraded shares of Sarepta Therapeutics from an “underweight” rating to a “neutral” rating and set a $24.00 price objective on the stock in a research note on Tuesday, July 29th. Finally, Morgan Stanley increased their price objective on shares of Sarepta Therapeutics from $15.00 to $20.00 and gave the company an “equal weight” rating in a report on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $33.75.

Sarepta Therapeutics Trading Up 15.2%

Shares of NASDAQ:SRPT opened at $18.67 on Wednesday. The company has a market cap of $1.82 billion, a PE ratio of -21.46 and a beta of 0.52. The company’s 50-day moving average price is $20.33 and its 200 day moving average price is $26.23. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $138.81. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The company’s revenue for the quarter was down 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.62 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Ancora Advisors LLC increased its holdings in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 300 shares in the last quarter. Byrne Asset Management LLC acquired a new position in shares of Sarepta Therapeutics in the 3rd quarter valued at $33,000. Banque Transatlantique SA acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $44,000. Pandora Wealth Inc. acquired a new position in shares of Sarepta Therapeutics in the 1st quarter valued at $45,000. Finally, Brooklyn Investment Group boosted its position in shares of Sarepta Therapeutics by 450.4% in the 1st quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 590 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.